# Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone

> **NCT01257412** · PHASE3 · SUSPENDED · sponsor: **AstraZeneca** · enrollment: 375 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Dapagliflozin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01257412
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2012-01
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 375 (ESTIMATED)
- **Why stopped:** FSI delayed until 15 January 2013
- **Last updated:** 2012-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01257412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01257412, "Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01257412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*